Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses

Despite the widespread use of SARS-CoV-2–specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2–specific T cell responses has been unknown, resulting in uncertainty as to whether anti–SARS-CoV-2 mAb administration m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramirez, Sydney I., Grifoni, Alba, Weiskopf, Daniela, Parikh, Urvi M., Heaps, Amy, Faraji, Farhoud, Sieg, Scott F., Ritz, Justin, Moser, Carlee, Eron, Joseph J., Currier, Judith S., Klekotka, Paul, Sette, Alessandro, Wohl, David A., Daar, Eric S., Hughes, Michael D., Chew, Kara W., Smith, Davey M., Crotty, Shane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869965/
https://www.ncbi.nlm.nih.gov/pubmed/36378539
http://dx.doi.org/10.1172/jci.insight.163471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869965/
https://www.ncbi.nlm.nih.gov/pubmed/36378539
http://dx.doi.org/10.1172/jci.insight.163471

Ejemplares similares